← Markets

Dianthus Therapeutics, Inc.

DNTH · NASDAQ

Market closed$105.60$10.25 (+10.75%)After hours $106.70 · +1.04%

Key statistics

Previous close$95.35
Open$93.33
Day high$105.74
Day low$91.01
52-week high$105.72
52-week low$18.08
Market cap4.41B
Volume1.03M
Average volume950.55K
P/E ratio-25.57
Forward P/E—
EPS-4.13
Dividend yield0.00%

Market context

Why it moved

DNTH surged sharply after Dianthus Therapeutics announced the kickoff of its Phase 3 EMERGE clinical trial, igniting strong investor optimism about the company's drug development pipeline.

Yahoo FinanceStockstotradeYahoo FinanceYahoo FinanceYahoo Finance

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Dianthus Therapeutics surged to a new 52-week high after announcing the initiation of the global, randomized, placebo-controlled Phase 3 EMERGE trial of claseprubart in approximately 195 generalized myasthenia gravis patients who are acetylcholine receptor antibody positive, with primary endpoint data expected in 2H 2028. The pivotal trial launch marks a major clinical inflection point for the company, driving shares up over 10% — outperforming the flat healthcare sector (XLV) — amid broad analyst support from Raymond James (Strong Buy), Guggenheim (Buy), TD Cowen (Buy), and Wolfe Research (Outperform), with shares extending gains in after-hours trading to near $107.

10.7499

July 17, 2026Dianthus Therapeutics fell nearly 5%, retreating from near its 52-week high amid notable insider selling activity. The company's CFO Ryan Savitz sold $3.16 million in shares on July 9 under a pre-planned 10b5-1 trading plan, leaving him with zero directly held common shares. Despite the pullback, analyst sentiment remains broadly constructive — Raymond James holds a Strong Buy with a $125 target, and Guggenheim maintains a Buy with a $200 target, citing competitive advantages after a rival Sanofi trial halt. The broader healthcare ETF (XLV) also declined modestly, while the S&P 500 slipped as tech-driven pressure weighed on sentiment.

-4.5641

July 16, 2026Dianthus Therapeutics closed modestly lower, pulling back from near its 52-week high of $102.37, as investors digested a CFO share sale of ~$3.16 million executed July 9 under a pre-planned Rule 10b5-1 trading plan. Despite the insider transaction, analyst sentiment remains broadly constructive: Raymond James holds a Strong Buy with a $125 target, Guggenheim maintains Buy with a $200 target citing competitive tailwinds after a rival Sanofi trial halt, and the company's Phase 3 EMERGE trial for claseprubart in generalized Myasthenia Gravis is underway following strong CIDP data. The stock has surged ~387% over the past year.

-1.3527

July 14, 2026Dianthus Therapeutics rose nearly 3% in regular trading and extended gains to roughly 5% in after-hours, touching a new 52-week high of $102.37 intraday, amid continued strong analyst conviction. Raymond James holds a Strong Buy with a $125 target while Guggenheim maintains a Buy and a $200 target, bolstered by a competitor's trial halt at Sanofi that analysts say benefits Dianthus's claseprubart program in CIDP and myasthenia gravis. A CFO share sale of ~$3.16M under a pre-planned 10b5-1 trading plan drew attention but was offset by the broader bullish narrative around a 387% one-year return.

2.6764

July 10, 2026Dianthus Therapeutics closed down over 2% as investors weighed whether the strong year-to-date rally — up more than 150% YTD and over 7x in the past year — has already priced in the pivotal Phase 3 EMERGE trial launch for claseprubart in generalized Myasthenia Gravis. The EMERGE trial, formally initiated in late May and still enrolling, represents a key de-risking milestone for the clinical-stage biotech, but analysts are questioning upside potential at current valuations (~4.6x P/B). The pullback comes amid a broadly supportive biotech backdrop, with XLV at record highs and Jim Cramer calling biotech the market's hottest group, though longer-term headwinds from Medicaid cuts under the One Big Beautiful Bill Act are emerging as a sector-wide concern.

-2.4293

July 9, 2026Dianthus Therapeutics gained despite a broad market risk-off session triggered by renewed U.S.-Iran tensions and surging oil prices, closing near its 52-week high. The advance was underpinned by a fresh update to its Phase 3 EMERGE trial for claseprubart (DNTH103) in generalized myasthenia gravis, signaling the pivotal program is active and enrolling. The move also benefited from bullish sector tailwinds, with healthcare outperforming for a second consecutive week, Jim Cramer calling biotech the 'hottest group in the market,' and Wall Street analysts issuing bullish commentary on DNTH specifically.

2.4123

July 3, 2026Dianthus Therapeutics gained nearly 4.6% after investor enthusiasm carried over from the June 29 initiation of the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis (gMG), building on strong Phase 2 MaGic data and recent FDA Orphan Drug Designation. The stock outperformed a healthcare sector (XLV) that closed near 52-week highs, aided by a soft June jobs report that eased rate-hike fears; analysts hold a consensus Buy with an average target of ~$127.67, implying significant upside, while near-term catalysts include MMN data expected in Q4'26 and a CIDP update by year-end.

4.5782

July 2, 2026Dianthus Therapeutics tumbled roughly 7.5% in above-average volume, pulling back sharply despite the recent positive catalyst of initiating its Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis. The selloff appears tied to index-related selling pressure, as DNTH was dropped from multiple Russell benchmarks — including the Russell 2000 Value, Russell 3000E, and Russell Microcap Value indexes — effective late June, forcing passive funds to unwind positions. The broader healthcare sector (XLV) held relatively flat, underscoring that the decline was largely stock-specific rather than sector-driven.

-7.4579

timothysykes.com · July 17, 2026Dianthus Therapeutics DNTH Jumps As Phase 3 EMERGE Trial Kicks OffSimply Wall Street · July 9, 2026Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In?Simply Wall Street · July 1, 2026Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG TrialInvesting.com · June 10, 2026Guggenheim reiterates Dianthus stock rating citing potency edgeSeeking Alpha · May 30, 2026Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win (NASDAQ:DNTH)Stock Titan · March 11, 2026Biotech Dianthus prices $625M deal to advance autoimmune drugs
Mt Newswire · June 29, 2026Dianthus Therapeutics Begins Phase 3 Trial of Treatment for Rare Autoimmune Disorder
Benzinga · June 12, 2026Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Mt Newswire · May 6, 2026Wedbush Adjusts Price Target on Dianthus Therapeutics to $105 From $103, Maintains Outperform Rating
Benzinga · May 6, 2026Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $105
Benzinga · May 5, 2026Dianthus Therapeutics Q1 EPS $(0.85) Beats $(1.07) Estimate, Sales $463.000K Beat $354.214K Estimate
Mt Newswire · May 5, 2026Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q1 Revenue $463K, vs. FactSet Est of $404K
Benzinga · April 9, 2026Wolfe Research Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $98
Mt Newswire · April 1, 2026Dianthus Therapeutics Insider Sold Shares Worth $9,492,596, According to a Recent SEC Filing

Peers

S&P 500SPX · $7,457.69-1.01%Relay Therapeutics, Inc.RLAY · $19.91+2.79%Bicycle Therapeutics plcBCYC · $4.21+0.72%Kura Oncology, Inc.KURA · $10.86-0.28%Autolus Therapeutics plcAUTL · $1.44-1.37%Stoke Therapeutics, Inc.STOK · $29.05-0.21%argenx SEARGX · $860.55+0.30%AstraZeneca PLCAZN · $168.90-0.23%SanofiSNY · $44.66+1.02%Beam Therapeutics Inc.BEAM · $27.53-3.03%Oruka Therapeutics, Inc.ORKA · $92.70+11.63%Celcuity Inc.CELC · $88.38+0.10%